Spinal cord metastasis in a patient treated with bevacizumab for glioblastoma

Spinal metastases from glioblastoma are extremely rare and may be misdiagnosed leading to a delay in investigation and treatment. Patient outcomes are poor with a high morbidity and mortality. Metastases are seen in the context of increasing survival due to improvements in glioblastoma therapies. We...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Targeted oncology 2013-06, Vol.8 (2), p.153-155
Hauptverfasser:	Lomax, Anna J., Yannakou, Costas K., Rosenthal, Mark A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Angiogenesis Inhibitors - adverse effects Angiogenesis Inhibitors - therapeutic use Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Bevacizumab Biological and medical sciences Biomedicine Brain Neoplasms - drug therapy Brain Neoplasms - pathology Day-to-Day Practice Diseases of the osteoarticular system Glioblastoma - drug therapy Glioblastoma - pathology Glioblastoma - secondary Humans Male Medical sciences Medicine Medicine & Public Health Neurology Oncology Spinal Cord Neoplasms - drug therapy Spinal Cord Neoplasms - pathology Spinal Cord Neoplasms - secondary Tumors of striated muscle and skeleton Tumors of the nervous system. Phacomatoses
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Spinal metastases from glioblastoma are extremely rare and may be misdiagnosed leading to a delay in investigation and treatment. Patient outcomes are poor with a high morbidity and mortality. Metastases are seen in the context of increasing survival due to improvements in glioblastoma therapies. We report a case of a patient developing a thoracic spinal cord metastasis while receiving anti-angiogenesis therapy with bevacizumab.
ISSN:	1776-2596 1776-260X
DOI:	10.1007/s11523-013-0270-0